Drug · CHEMBL414804
OXALIPLATIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. OXALIPLATIN. Drugs and targets, record CHEMBL414804. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL414804
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- JM-83, L-OHP, MBP-426 (LIPOSOMAL OXALIPLATIN), NSC-266046, Oxaliplatine, Oxaliplatino, RP-54780, SR-96669, Xaliplatin
- ChEMBL
- Open Targets' highest stage
- Approval, for 7 of its 157 diseases, from ATC, ClinicalTrials.gov, PMDA and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases157
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| colorectal cancer | Approval | TTD | 538 | 537 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
| gastric cancer | Phase 3 | ClinicalTrials.gov | 293 | 293 | https://conductscience.org/library/drugs?q=MONDO_0001056 |
| rectal cancer | Phase 3 | ClinicalTrials.gov | 244 | 244 | https://conductscience.org/library/drugs?q=MONDO_0006519 |
| gastric adenocarcinoma | Phase 3 | ClinicalTrials.gov | 236 | 236 | https://conductscience.org/library/drugs?q=MONDO_0005036 |
| gastroesophageal junction adenocarcinoma | Phase 3 | ClinicalTrials.gov | 213 | 213 | https://conductscience.org/library/drugs?q=MONDO_0003219 |
| malignant pancreatic neoplasm | Approval | ClinicalTrials.gov | 138 | 138 | https://conductscience.org/library/drugs?q=MONDO_0009831 |
| pancreatic neoplasm | Approval | ClinicalTrials.gov | 136 | 136 | https://conductscience.org/library/drugs?q=MONDO_0021040 |
| pancreatic adenocarcinoma | Phase 3 | ClinicalTrials.gov | 119 | 119 | https://conductscience.org/library/drugs?q=MONDO_0006047 |
| hepatocellular carcinoma | Approval | ClinicalTrials.gov | 101 | 101 | https://conductscience.org/library/drugs?q=MONDO_0007256 |
| malignant colon neoplasm | Approval | PMDA | 87 | 86 | https://conductscience.org/library/drugs?q=MONDO_0021063 |
1 to 10 of 157Source Open Targets
See all 157 diseasesTrials2,306
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 34 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 240 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00112918 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer | Phase 3 | 3,451 | 2012-09-06 | oxaliplatin | Its name | ClinicalTrials.gov |
| NCT00079274 | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer | Phase 3 | 3,397 | 2015-02-09 | oxaliplatin | Its name | ClinicalTrials.gov |
| NCT00096278 | Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer | Phase 3 | 2,710 | 2012-12-03 | oxaliplatin | Its name | ClinicalTrials.gov |
| NCT01150045 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery | Phase 3 | 2,527 | 2021-08-06 | oxaliplatin | Its name | ClinicalTrials.gov |
| NCT00217737 | Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Phase 3 | 2,431 | 2025-07-20 | oxaliplatin | Its name | ClinicalTrials.gov |
| NCT00265850 | Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | Phase 3 | 2,334 | 2017-04-26 | oxaliplatin | Its name | ClinicalTrials.gov |
| NCT00069095 | A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer | Phase 3 | 2,035 | 2016-01-22 | oxaliplatin | Its name | ClinicalTrials.gov |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Phase 3 | 2,031 | 2022-06-28 | oxaliplatin | Its name | ClinicalTrials.gov |
| NCT00069121 | A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer | Phase 3 | 1,886 | 2011-07-29 | oxaliplatin | Its name | ClinicalTrials.gov |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX | Phase 2/3 | 1,814 | 2012-11-28 | oxaliplatin | Its name | ClinicalTrials.gov |
1 to 10 of 2,306
See all 2,306 trialsComparisons in its trials261
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Oxaliplatin + Leucovorin + 5-Fluorouracil vs Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab: serious adverse events | 81 of 1,326 | 270 of 1,334 | 2,660 | NCT00096278 | Trial comparisons |
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE) | 267 of 785 | 206 of 787 | 1,572 | NCT03675737 | Trial comparisons |
| Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Experienced an Adverse Event (AE) | 776 of 785 | 771 of 787 | 1,572 | NCT03675737 | Trial comparisons |
| Panitumumab Plus FOLFOX vs FOLFOX Alone: serious adverse events | 262 of 585 | 198 of 584 | 1,169 | NCT00364013 | Trial comparisons |
| Arm A: FOLFOX or FOLFIRI + Bevacizumab vs Arm B: FOLFOX or FOLFIRI + Cetuximab: serious adverse events | 98 of 559 | 111 of 578 | 1,137 | NCT00265850 | Trial comparisons |
| Group 1 vs Group 2: Overall Survival | 74 of 585 | 67 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: DFS | 114 of 585 | 113 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: Local Recurrence (TLR): | 9 of 585 | 7 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: Rates of Receiving Pre- or Post-operative 5FUCMT | 61 of 585 | 543 of 543 | 1,128 | NCT01515787 | Trial comparisons |
| Group 1 vs Group 2: deaths from any cause | 74 of 585 | 67 of 543 | 1,128 | NCT01515787 | Trial comparisons |
1 to 10 of 261
See all 261 comparisons in its trialsPapers from its trials1,339
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL414804
GET https://conductscience.org/api/drugs/v1/CHEMBL414804/diseases?page=2